SG11201509012QA - Sobetirome in the treatment of myelination diseases - Google Patents

Sobetirome in the treatment of myelination diseases

Info

Publication number
SG11201509012QA
SG11201509012QA SG11201509012QA SG11201509012QA SG11201509012QA SG 11201509012Q A SG11201509012Q A SG 11201509012QA SG 11201509012Q A SG11201509012Q A SG 11201509012QA SG 11201509012Q A SG11201509012Q A SG 11201509012QA SG 11201509012Q A SG11201509012Q A SG 11201509012QA
Authority
SG
Singapore
Prior art keywords
sobetirome
treatment
myelination diseases
myelination
diseases
Prior art date
Application number
SG11201509012QA
Other languages
English (en)
Inventor
Meredith Hartley
Andrew Placzek
Marco Righi
Dennis Bourdette
Gail Marracci
Priya Chaudhary
Original Assignee
Univ Oregon Health & Science
Us Dept Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oregon Health & Science, Us Dept Veterans Affairs filed Critical Univ Oregon Health & Science
Publication of SG11201509012QA publication Critical patent/SG11201509012QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SG11201509012QA 2013-05-03 2014-02-05 Sobetirome in the treatment of myelination diseases SG11201509012QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361819467P 2013-05-03 2013-05-03
PCT/US2013/053640 WO2014178892A1 (en) 2013-05-03 2013-08-05 Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
PCT/US2014/014943 WO2014178931A1 (en) 2013-05-03 2014-02-05 Sobetirome in the treatment of myelination diseases

Publications (1)

Publication Number Publication Date
SG11201509012QA true SG11201509012QA (en) 2015-11-27

Family

ID=51843844

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201709090UA SG10201709090UA (en) 2013-05-03 2014-02-05 Sobetirome in the treatment of myelination diseases
SG11201509012QA SG11201509012QA (en) 2013-05-03 2014-02-05 Sobetirome in the treatment of myelination diseases

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201709090UA SG10201709090UA (en) 2013-05-03 2014-02-05 Sobetirome in the treatment of myelination diseases

Country Status (13)

Country Link
US (3) US10226438B2 (de)
EP (1) EP2991670B8 (de)
JP (4) JP2016517883A (de)
CN (1) CN105431163A (de)
AU (1) AU2014260468A1 (de)
BR (1) BR112015027682A2 (de)
CA (1) CA2911309A1 (de)
ES (1) ES2745532T3 (de)
HK (1) HK1222552A1 (de)
MX (2) MX2015015228A (de)
RU (1) RU2015151216A (de)
SG (2) SG10201709090UA (de)
WO (2) WO2014178892A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014178892A1 (en) 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
AU2015253100B2 (en) 2014-04-30 2018-01-18 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
JP6342575B2 (ja) 2014-08-13 2018-06-13 ザ・ジョンズ・ホプキンス・ユニバーシティー 脳腫瘍への選択的デンドリマー送達
EP3368088B1 (de) * 2015-10-29 2023-06-07 The Johns Hopkins University Zusammensetzungen und verfahren zur behandlung von peroxisomalen erkrankungen und leukodystrophien
WO2017185087A1 (en) 2016-04-22 2017-10-26 Viking Therapeutics Use of thyroid beta-agonists
CN110200978B (zh) * 2016-04-22 2023-10-31 维京治疗股份有限公司 甲状腺β-激动剂的应用
PT3457851T (pt) 2016-05-18 2021-09-28 Univ Oregon Health & Science Derivados de sobetiroma
MX2019001634A (es) * 2016-08-12 2019-08-29 Univ Oregon Health & Science Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
WO2018183940A1 (en) * 2017-03-31 2018-10-04 Neurovia, Inc. Methods and compositions for treating niemann-pick disease
CN110913916A (zh) 2017-04-27 2020-03-24 约翰霍普金斯大学 用于血管造影的树状聚合物组合物
WO2018208707A1 (en) * 2017-05-08 2018-11-15 Neurovia, Inc. Methods and compositions for treating demyelinating diseases
US10780069B2 (en) * 2017-05-18 2020-09-22 University of Pittsburgh—of the Commonwealth System of Higher Education Use of GC-1 in transplant related population
WO2019005816A1 (en) 2017-06-29 2019-01-03 Yale University COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING FIBROUS PULMONARY DISEASES
US11633433B2 (en) * 2017-07-18 2023-04-25 Keio University Anti-bacterial composition against TH1 cell-inducing bacteria
JP7383297B2 (ja) 2017-11-10 2023-11-20 ザ・ジョンズ・ホプキンス・ユニバーシティー デンドリマー送達システムおよびそれを使用する方法
WO2020123861A1 (en) 2018-12-12 2020-06-18 Autobahn Therapeutics, Inc. Novel thyromimetics
CA3130371A1 (en) 2019-03-01 2020-09-10 Autobahn Therapeutics, Inc. Novel thyromimetics
CA3163892A1 (en) 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to the eye
CN111116684B (zh) * 2019-12-31 2020-09-25 厦门甘宝利生物医药有限公司 一种具有甲状腺激素受体激动剂特性的肝靶向化合物及其药物组合物
CN115569233B (zh) * 2022-10-17 2023-07-14 湖南大学 既能吸光又能与自由基反应的高效光抑制剂的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
EP0873361B1 (de) 1995-12-13 2006-11-02 The Regents Of The University Of California Kristalle der mit einem Ligand komplexierten Ligandenbindedomäne des Schilddrüsenhormonrezeptors
JP3345428B2 (ja) 1996-08-20 2002-11-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 合成甲状腺ホルマン組成物を使用した眼の処置
US5883294A (en) 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
PT1089968E (pt) 1998-06-30 2005-08-31 Univ California Analogos de hormona tiroideia e metodos para a sua preparacao
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US7302347B2 (en) 2002-12-10 2007-11-27 The Regents Of The University Of California Method for creating specific, high affinity nuclear receptor pharmaceuticals
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
CA2539288C (en) * 2003-09-15 2015-05-12 Shaker A. Mousa Thyroid hormone analogs and methods of use
WO2006012015A2 (en) * 2004-06-29 2006-02-02 Oregon Health And Science University Methods and compositions for nerve regeneration
JP2008513461A (ja) * 2004-09-15 2008-05-01 オードウェイ リサーチ インスティテュート 血管形成を促進する甲状腺ホルモンアナログ
WO2006105205A1 (en) 2005-03-29 2006-10-05 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
KR20090071652A (ko) * 2006-10-20 2009-07-01 바이오겐 아이덱 엠에이 인코포레이티드 가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료
CN101610774B (zh) * 2006-11-03 2012-04-04 萨斯喀彻温大学 治疗脱髓鞘疾病的方法
FI20075245A0 (fi) * 2007-04-11 2007-04-11 Markku Ahotupa Menetelmä oksidatiivisen metabolian arvioimiseksi
CA2970273C (en) 2007-07-11 2020-04-14 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
CN102014957B (zh) * 2008-04-21 2014-12-10 奥德纳米有限公司 用于治疗耳部疾病和病况的耳用调配物
AU2010262738A1 (en) 2009-05-20 2011-10-13 Lingual Consegna Pty Ltd Buccal and/or sublingual therapeutic formulation
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
JP5786195B2 (ja) 2010-12-16 2015-09-30 シナプサス セラピューティクス,インコーポレーテッド 舌下フィルム
WO2014063720A1 (en) * 2012-10-25 2014-05-01 Renault Trucks Electronically controlled pneumatic brake system for an automotive vehicle, automotive vehicle equipped with such a system and method for controlling such a system
WO2014178892A1 (en) * 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy

Also Published As

Publication number Publication date
US11510887B2 (en) 2022-11-29
JP2018162321A (ja) 2018-10-18
JP2016517884A (ja) 2016-06-20
US20190175531A1 (en) 2019-06-13
EP2991670B1 (de) 2019-07-03
CN105431163A (zh) 2016-03-23
RU2015151216A (ru) 2017-06-08
BR112015027682A2 (pt) 2017-08-29
WO2014178931A1 (en) 2014-11-06
WO2014178931A8 (en) 2015-11-26
JP2016517883A (ja) 2016-06-20
EP2991670B8 (de) 2019-09-11
ES2745532T3 (es) 2020-03-02
HK1222552A1 (zh) 2017-07-07
SG10201709090UA (en) 2017-12-28
EP2991670A4 (de) 2017-01-18
US10226438B2 (en) 2019-03-12
WO2014178892A1 (en) 2014-11-06
MX2015015228A (es) 2016-10-03
WO2014178892A8 (en) 2015-12-17
CA2911309A1 (en) 2014-11-06
AU2014260468A1 (en) 2015-11-19
US20200405669A1 (en) 2020-12-31
MX2021000538A (es) 2021-04-28
EP2991670A1 (de) 2016-03-09
US20160081955A1 (en) 2016-03-24
JP6360552B6 (ja) 2018-08-15
JP6360552B2 (ja) 2018-07-18
JP2018141024A (ja) 2018-09-13

Similar Documents

Publication Publication Date Title
HK1222552A1 (zh) 索布替羅用於治療髓鞘形成疾病
IL286759A (en) Therapeutic methods and preparations
GB201320729D0 (en) Therapeutic compounds and their use
GB201321743D0 (en) Therapeutic agents
IL239368A0 (en) Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system
GB201321738D0 (en) Therapeutic Agents
GB201321729D0 (en) Therapeutic agents
GB201321733D0 (en) Therapeutic agents
GB201321728D0 (en) Therapeutic agents
GB201321739D0 (en) Therapeutic agents
GB201321730D0 (en) Therapeutic agents
GB201321732D0 (en) Therapeutic agents
GB201321734D0 (en) Therapeutic Agents
GB201321737D0 (en) Therapeutic Agents
EP2967062A4 (de) Desethylhydroxychloroquin zur behandlung von erkrankungen in zusammenhang mit entzündungen
GB201321735D0 (en) Therapeutic Agents
HK1215164A1 (zh) 處理方法
ZA201500547B (en) Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
GB201321731D0 (en) Therapeutic agents
GB201308440D0 (en) Therapeutic
GB2516814B (en) Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
PT2872176T (pt) Carboranilporpirinas para utilização no tratamento de cancro
GB201311361D0 (en) Compounds and their therapeutic use
GB201318668D0 (en) Sonosensitive therapeutic
GB201308736D0 (en) Compounds and their therapeutic use